Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | DCK | P27707 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19398586 | 0.88 | CHRNA7 (0.55) | CHRNA7TRPM8KDM4ESMN1; SMN2MAPT | |
| SCHEMBL19399180 | 0.80 | CHRNA7 (0.60) | CHRNA7TRPM8KDM4ESMN1; SMN2MAPT | |
| SCHEMBL23964628 | 0.73 | CHRNA7 (0.54) | CHRNA7TRPM8KDM4ESMN1; SMN2MAPT | |
| SCHEMBL19378302 | 0.68 | CHRNA7 (1.00) | CHRNA7KDM4EMAPT | |
| SCHEMBL19398597 | 0.67 | CHRNA7 (0.38) | CHRNA7TRPM8KDM4EMAPT | |
| SCHEMBL4607588 | 0.64 | KDM4E (0.43) | CHRNA7TRPM8KDM4ESMN1; SMN2DCK | |
| SCHEMBL4606885 | 0.63 | CHRNA7 (0.48) | CHRNA7TRPM8KDM4ESMN1; SMN2 | |
| SCHEMBL4604558 | 0.62 | CHRNA7 (0.38) | CHRNA7TRPM8KDM4ESMN1; SMN2 | |
| SCHEMBL19405335 | 0.62 | CHRNA7 (0.38) | CHRNA7TRPM8KDM4ESMN1; SMN2MAPT | |
| SCHEMBL18924618 | 0.61 | SMN1; SMN2 (0.68) | KDM4ESMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030007-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030007-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | CHRNA7 1/4885TRPM8 428/4885KDM4E 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.